Celcuity Inc. (NASDAQ:CELC – Get Free Report) saw a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 2,290,000 shares, a decline of 8.0% from the August 15th total of 2,490,000 shares. Based on an average trading volume of 370,300 shares, the short-interest ratio is presently 6.2 days.
Celcuity Price Performance
NASDAQ:CELC traded up $0.03 on Wednesday, hitting $15.01. The company had a trading volume of 213,726 shares, compared to its average volume of 282,679. Celcuity has a 52 week low of $8.39 and a 52 week high of $22.19. The company has a current ratio of 14.95, a quick ratio of 14.95 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $526.87 million, a price-to-earnings ratio of -5.39 and a beta of 0.76. The firm has a 50 day moving average of $16.79 and a two-hundred day moving average of $16.95.
Celcuity (NASDAQ:CELC – Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.09. During the same period in the prior year, the business posted ($0.66) EPS. On average, research analysts anticipate that Celcuity will post -2.54 earnings per share for the current year.
Hedge Funds Weigh In On Celcuity
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on the company. Stifel Nicolaus decreased their price objective on Celcuity from $40.00 to $39.00 and set a “buy” rating for the company in a research note on Thursday, August 15th. Lifesci Capital assumed coverage on Celcuity in a research report on Monday, August 26th. They set an “outperform” rating and a $27.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of Celcuity in a research report on Thursday, August 15th. Leerink Partnrs upgraded Celcuity to a “strong-buy” rating in a research note on Monday, July 22nd. Finally, Leerink Partners assumed coverage on shares of Celcuity in a research note on Monday, July 22nd. They set an “outperform” rating and a $29.00 price objective on the stock. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $28.67.
Check Out Our Latest Report on Celcuity
Celcuity Company Profile
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Further Reading
- Five stocks we like better than Celcuity
- What Does Downgrade Mean in Investing?
- This Is the Top Large-Cap Stock Insiders Are Buying
- Learn Technical Analysis Skills to Master the Stock Market
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
- 3 Tickers Leading a Meme Stock Revival
- Stocks to Take Advantage of Rising Gold Prices
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.